N/A
N=50
Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients
Colorectal Cancer (CRC)
Bottom Line
View on ClinicalTrials.gov: NCT00977613 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Feb 2011
Primary outcome: Primary: Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater — 18 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- exercise counseling (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Beth Israel Medical Center
- Primary completion
- Apr 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater |
18 | — |
| SECONDARY Disease-free Survival |
— | — |
| SECONDARY Recurrence-free Survival |
— | — |
| SECONDARY Overall Survival |
— | — |
Summary
Given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage II and III colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.
Eligibility Criteria
Inclusion Criteria
- Patients with histological confirmation of stage 2 or stage 3 colorectal cancer.
- Ability to sign written informed consent.
- WHO performance status of 2 or better.
- No evidence of recurrent disease or death prior to second questionnaire.
- Patients with declining physical activity within 90 days of second physical activity assessment will be excluded.
There are no exclusion criteria
Data sourced from ClinicalTrials.gov (NCT00977613). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.